LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,415,529
تعداد دریافت فایل اصل مقاله11,291,333
Saeedi, Anahita, Baghestani, Ahmadreza, Khadem Maboudi, Aliakbar, Farhangi, Hamid. (1399). Determining the Significant Prognostic Factors for the Recurrence of Pediatric Acute Lymphoblastic Leukemia Using a Competing Risks Approach. سامانه مدیریت نشریات علمی, 45(4), 304-310. doi: 10.30476/ijms.2020.83123.1188
Anahita Saeedi; Ahmadreza Baghestani; Aliakbar Khadem Maboudi; Hamid Farhangi. "Determining the Significant Prognostic Factors for the Recurrence of Pediatric Acute Lymphoblastic Leukemia Using a Competing Risks Approach". سامانه مدیریت نشریات علمی, 45, 4, 1399, 304-310. doi: 10.30476/ijms.2020.83123.1188
Saeedi, Anahita, Baghestani, Ahmadreza, Khadem Maboudi, Aliakbar, Farhangi, Hamid. (1399). 'Determining the Significant Prognostic Factors for the Recurrence of Pediatric Acute Lymphoblastic Leukemia Using a Competing Risks Approach', سامانه مدیریت نشریات علمی, 45(4), pp. 304-310. doi: 10.30476/ijms.2020.83123.1188
Saeedi, Anahita, Baghestani, Ahmadreza, Khadem Maboudi, Aliakbar, Farhangi, Hamid. Determining the Significant Prognostic Factors for the Recurrence of Pediatric Acute Lymphoblastic Leukemia Using a Competing Risks Approach. سامانه مدیریت نشریات علمی, 1399; 45(4): 304-310. doi: 10.30476/ijms.2020.83123.1188

Determining the Significant Prognostic Factors for the Recurrence of Pediatric Acute Lymphoblastic Leukemia Using a Competing Risks Approach

Iranian Journal of Medical Sciences
دوره 45، شماره 4، مهر 2020، صفحه 304-310    اصل مقاله (320.94 K)
نوع مقاله: Brief Report(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2020.83123.1188
نویسندگان
Anahita Saeedi1؛ Ahmadreza Baghestani* 2؛ Aliakbar Khadem Maboudi3؛ Hamid Farhangi4
1Department of Biostatistics, School of Paramedical Sciences, Shahid Beheshti University, Tehran, Iran
2Physiotherapy Research Center, Department of Biostatistics, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Department of Biostatistics, School of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4Department of Pediatrics Hematology and Oncology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
چکیده
Acute lymphoblastic leukemia (ALL) is the most common cause of cancer-related fatality among children. This study aimed to identify the significant prognostic factors for the incidence of pediatric ALL. This retrospective study, conducted from 2007 to 2016 in the Iranian city of Mashhad, enrolled 417 patients with ALL. The diagnosis was confirmed by Giemsa staining of bone marrow smears. The first recurrence was regarded as the event of interest and non-relapse mortality as the competing event through a three-parameter Gompertz model. The level of statistical significance for univariate and multivariate analyses was set at 0.2 and 0.05, respectively. The first recurrence occurred in 44 (10.6%) survivors. Disease-free survival and 5-year overall survival rates were 85.9% and 74%, correspondingly. The five-year incidence rate for the first recurrence was 11.5% in the presence of non-relapse mortality. Briefly, the characteristics of the Gompertz model conferred more effective prognostic factors. Age above 10 years (P=0.010), involvement of the central nervous system (P=0.050), a high white blood cell count (P=0.020), and tumor lysis syndrome (P=0.010) were the significant prognostic factors for the recurrence and mortality of ALL. Accordingly, careful monitoring in the administration of treatment protocols is suggested to reduce the risk of recurrence and death in these patients.
کلیدواژه‌ها
Survival analyses؛ Lymphoblastic leukemia؛ Acute؛ Childhood؛ Competing risks
سایر فایل های مرتبط با مقاله
مراجع
  1. Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015;373:1541-52. doi: 10.1056/NEJMra1400972. PubMed PMID: 26465987.
  2. Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120:1165-74. doi: 10.1182/blood-2012-05-378943. PubMed PMID: 22730540; PubMed Central PMCID: PMCPMC3418713.
  3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34. doi: 10.3322/caac.21551. PubMed PMID: 30620402.
  4. Katz AJ, Chia VM, Schoonen WM, Kelsh MA. Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden. Cancer Causes Control. 2015;26:1627-42. doi: 10.1007/s10552-015-0657-6. PubMed PMID: 26376890.
  5. Williams LA, Richardson M, Marcotte EL, Poynter JN, Spector LG. Sex ratio among childhood cancers by single year of age. Pediatr Blood Cancer. 2019;66:e27620. doi: 10.1002/pbc.27620. PubMed PMID: 30815990; PubMed Central PMCID: PMCPMC6472964.
  6. Lustosa de Sousa DW, de Almeida Ferreira FV, Cavalcante Felix FH, de Oliveira Lopes MV. Acute lymphoblastic leukemia in children and adolescents: prognostic factors and analysis of survival. Rev Bras Hematol Hemoter. 2015;37:223-9. doi: 10.1016/j.bjhh.2015.03.009. PubMed PMID: 26190424; PubMed Central PMCID: PMCPMC4519710.
  7. Kleinbaum DG, Klein M. Competing risks survival analysis. New York: Survival Analysis, Springer; 2012. p. 425-95.
  8. Daly ME. Determinants of platelet count in humans. Haematologica. 2011;96:10-3. doi: 10.3324/haematol.2010.035287. PubMed PMID: 21193429; PubMed Central PMCID: PMCPMC3012758.
  9. Zhang Z. Variable selection with stepwise and best subset approaches. Ann Transl Med. 2016;4:136. doi: 10.21037/atm.2016.03.35. PubMed PMID: 27162786; PubMed Central PMCID: PMCPMC4842399.
  10. Patel A, Tiwari A, Biswas B, Chand Sharma M, Vishnubhatla S, Bakhshi S. Clinical Predictors and Prognostic Model for Pediatric Lymphoblastic Lymphoma Treated With Uniform BFM90 Protocol: A Single-Center Experience of 65 Patients From Asia. Clin Lymphoma Myeloma Leuk. 2019;19:e291-e8. doi: 10.1016/j.clml.2019.01.008. PubMed PMID: 30905539.
  11. Marwaha RK, Kulkarni KP, Bansal D, Trehan A. Central nervous system involvement at presentation in childhood acute lymphoblastic leukemia: management experience and lessons. Leuk Lymphoma. 2010;51:261-8. doi: 10.3109/10428190903470323. PubMed PMID: 20038226.
  12. Munch V, Trentin L, Herzig J, Demir S, Seyfried F, Kraus JM, et al. Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor. Blood. 2017;130:643-54. doi: 10.1182/blood-2017-03-769315. PubMed PMID: 28550041.
  13. Alakel N, Middeke JM, Schetelig J, Bornhauser M. Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase. Onco Targets Ther. 2017;10:597-605. doi: 10.2147/OTT.S103864. PubMed PMID: 28203093; PubMed Central PMCID: PMCPMC5295804.
  14. Criscuolo M, Fianchi L, Dragonetti G, Pagano L. Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency. Expert Rev Hematol. 2016;9:197-208. doi: 10.1586/17474086.2016.1127156. PubMed PMID: 26629730.
  15. Hossain MJ, Xie L, McCahan SM. Characterization of pediatric acute lymphoblastic leukemia survival patterns by age at diagnosis. J Cancer Epidemiol. 2014;2014:865979. doi: 10.1155/2014/865979. PubMed PMID: 25309596; PubMed Central PMCID: PMCPMC4182848.
آمار
تعداد مشاهده مقاله: 2,893
تعداد دریافت فایل اصل مقاله: 1,732


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب